학술논문

KEYNOTE-495/KEYIMPACT: UPDATED ANALYSIS OF A BIOMARKER-DIRECTED, RANDOMIZED, PHASE 2 TRIAL OF PEMBROLIZUMAB-BASED COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER